Business
Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications Management to host a conference call and webcast today at 4:30
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications \nManagement to host a conference call and webcast today at 4:30 p.m. EDT\nNEW HAVEN, Conn., March 16, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced financial results for the quarter and year ended December 31, 2022, as well as provided business updates.\n\n \n \n \n \n \n \n\n \nTrevi has multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications\"Following the very encouraging results from our Phase 2 CANAL trial in IPF chronic cough, we have entered a transformational period in the development of Haduvio for the treatment of serious chronic cough conditions,\" said Jennifer Good, President and CEO of Trevi Therapeutics. \"With a strong balance sheet and cash runway expected into 2026, we are well-positioned to develop Haduvio as a pipeline in a product, supported by the differentiated central and peripheral mechanism of action of Haduvio.\"\n2022 Fourth Quarter and Year End Business Highlights\nPresented final data from the Phase 2 CANAL Trial of Haduvio for the treatment of chronic cough in IPF at the British Thoracic Society's Winter Meeting.Appointed David Clark, MD, MRCP, as Chief Medical Officer.Initiated the Human Abuse Liability study for Haduvio.Ended 2022 with cash, cash equivalents, and marketable securities of $120.5 million.Key Business Updates\nIPF Chronic Cough Clinical Trials The Company is planning to conduct a Phase 2b dose ranging trial of Haduvio for the treatment of chronic cough in IPF patients. The objective of the trial is to determine the dose response of Haduvio in this IPF patient population. The Company expects to initiate this dose ranging study in the second half of 2023.\nThe Company is also planning a Phase 1b study to evaluate the effect of Haduvio on respiratory physiology in IPF patients of varying disease severity. The Company is in discussions with the U.S. Food and Drug Administration (FDA) regarding the design of this trial and expects to start this trial in ...